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Summary 
Advanced glycosylation endproducts (AGEs) are derived from the nonenzymatic addition of glucose 
to proteins. AGEs have been found to accumulate on tissue proteins in patients with diabetes, 
and their accumulation is thought to play a role in the development of diabetic complications. 
The finding that macrophages and endothelial cells contain AGE-specific  receptors led us to examine 
whether mesangial cells (MCs) also possess a mechanism for recognizing and processing AGEs. 
Membrane extracts  isolated from rat and human MCs were found to bind AGE-bovine serum 
albumin (BSA) in a saturable  fashion, with a binding affinity of 2.0  _+  0.4  x  106 M-1 (500 
nM). The binding was specific for the AGE adduct, since AGE-modified collagen I and ribonuclease 
both competitively inhibited nSI-AGE-BSA binding to MC membranes, while the unmodified 
proteins did not compete. Binding of AGE proteins was followed by slow internalization and 
degradation of the ligand. Ligand blotting of MC membrane extracts demonstrated three distinct 
AGE-binding membrane proteins of 50, 40, and 30 kD. Growth of MCs on various AGE-modified 
matrix proteins resulted in alterations in MC function, as demonstrated by enhanced production 
of fibronectin and decreased  proliferation. These results point to the potential role that the interaction 
of AGE-modified proteins with MCs may play in vivo in promoting diabetic kidney disease. 
I 
n diabetes  mellitus, expansion of the glomerular mesan- 
gium correlates with the clinical features of diabetic kidney 
disease, including albuminuria, hypertension, and decreased 
glomerular filtration rate (1-3).  Mesangial  expansion leads 
to a decrease in glomerular filtration rate by impinging on 
the glomerular capillary vasculature,  thereby decreasing the 
filtering surface of the glomerulus. The increase in mesan- 
gial matrices is due primarily to the accumulation of normal 
matrix proteins, including collagens  type IV and type V, 
laminin, and fibronectin (4, 5). While it is generally agreed 
that the altered physical milieu in diabetes is responsible for 
the development of diabetic kidney disease, the mechanisms 
by which hyperglycemia might lead to mesangial expansion 
are still poorly defined. 
Experimental data have accumulated linking the forma- 
tion  of  advanced  glycosylation  endproducts  (AGEs) 1 to 
many of the complications of diabetes (6, 7). AGEs are de- 
rived from early products of nonenzymatic glycosylation, and 
are formed slowly from the early Amadori product after a 
' Abbreviations used in this  paper: AGE, advanced glycosylation endproduct; 
EC, endothelial cell; MC,  mesangial  cell. 
series of reactions and rearrangements. AGEs, which repre- 
sent irreversible late reacting products, are characterized  by 
brown color, fluorescence, and their ability to cause protein- 
to-protein crosslinking (6, 7). AGE compounds have also been 
shown to bind to specific receptors on murine and human 
monocyte/macrophages, as well as bovine and human en- 
dothelial cells. Since AGEs form progressively as a function 
of time, it is hypothesized that under normal conditions, the 
function of AGE receptors is partly to signal cells such as 
the macrophage to promote turnover of aging tissue proteins 
and cells (8,  9).  Under conditions of normoglycemia, the 
removal of AGE-modified proteins occurs conceivably  at a 
rate sufficient to keep up with the production of new AGE 
proteins, preventing overt accumulation of AGE-modified pro- 
teins. However, in diabetes, excessive formation of AGEs in 
the presence of continuously elevated blood glucose may over- 
whelm the body's ability to remove AGEs, resulting in a net 
excess of AGEs on most structural tissue proteins (10). This 
hypothesis is supported by the demonstration that AGEs ac- 
cumulate at an accelerated rate in diabetics on long-lived ma- 
trix proteins in the kidney and blood vessel wall (8, 11). Re- 
cent  experimental evidence  suggested that  interaction  of 
AGE-modified proteins with macrophages and endothelial 
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AGEs, but can also modulate cellular function (12, 13). Mac- 
rophages, upon interaction with AGEs,  are induced to re- 
lease  the  cytokines cachectin/TNF,  IL-1, platelet-derived 
growth factor, and insulin-like growth factor I (12, 14, 15). 
Under conditions of normoglycemia, this response may be 
beneficial,  aiding  in  the  removal  of  AGE  proteins  and 
promoting normal tissue remodeling. However, excessive  for- 
mation of AGEs in diabetics  may lead to an exaggerated re- 
sponse, resulting in excessive production of these factors, all 
of which could contribute to diabetic complications such as 
premature development of atherosclerotic plaques or mesan- 
gial expansion in the kidney. More direct evidence supporting 
a role for AGE receptor interaction in the development of 
diabetic complications derives from experiments performed 
with cultured ECs (13). The interaction of ECs with AGEs 
induces several changes in EC function that are characteristic 
of diabetes, including an increase in EC permeability and an 
increase  in EC procoagulant properties. 
Since mesangial cells are primarily responsible for the main- 
tenance of the glomerular mesangium (16, 17), we hypothe- 
sized that they may contain binding sites for AGE-modified 
proteins via which they may participate in the turnover of 
these proteins. In addition, we hypothesized that the accumu- 
lation of AGEs on mesangial matrix proteins in diabetes could 
directly modify mesangial cell (MC) function, resulting in 
altered proliferation and/or synthesis of matrix proteins. Our 
results indicate that MCs specifically bind AGE-modified pro- 
teins in a saturable fashion. In addition, MCs plated onto 
AGE-modified matrices demonstrate functional changes, in- 
cluding enhanced production of fibronectin and decreased 
proliferation. These results point to the potential role that 
the interaction of AGE-modified matrix proteins with na- 
tive cells may play in vivo in promoting diabetic kidney disease. 
Materials and Methods 
Cell Culture.  Primary cultures of rat MCs were obtained from 
outgrowths of isolated rat glomeruli by Dr. M. Ganz (Yale Univer- 
sity, New Haven, CT), as previously described (18, 19). In brief, 
rats were anesthetized  with ether and the kidneys  were excised  under 
sterile conditions. After removing the kidney capsule, the kidney 
cortices were isolated, minced to a fine paste with a razor blade, 
and then pressed through serial stainless  steel sieves (Nos. 140, 80, 
and 200; Fisher Scientific Co., Pittsburgh,  PA). Glomeruli were 
collected from the top of the 75-/~m sieve. This process resulted 
in >98% pure glomeruli. The glomeruli were then pelleted and 
resuspended in DMEM supplemented with 20% FCS, 5/~g/ml 
bovine insulin, 2 mM t-glutamine, and 40/~g/ml gentamicin. The 
glomerular suspensions were plated onto tissue culture flasks and 
incubated at 37~  in 5% CO2. Primary cultures were allowed to 
grow for 3-4 wk, at which time the MCs were confluent. MCs 
were used between the fourth and ninth passages. The purity of 
the rat MC populations was documented by several  criteria (18-20). 
The MCs exhibited a uniform straplike appearance and stained  posi- 
tively for Thy 1-1 antigen, myosin, and actin. They were sensitive 
to mitomycin  C, a MC toxin, but were resistant to the aminonucleo- 
side puromycin, an epithelial cell toxin. Fibroblast contamination 
was excluded by demonstrating the ability of the cells to grow in 
media in which t-valine had been substituted for D-valine. In addi- 
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tion, they stained negative for factor VIII and cytokeratin. Over 
the experimental  period, they continued to maintain a uniform stel- 
late appearance. 
Human MC were provided by Dr. J. Floege and Dr. K. Resch 
(Hannover, FRG), prepared as previously described in detail (21). 
In brief, normal human kidney tissue was obtained from nephrec- 
tomy specimens. Renal cortices were homogenized and glomeruli 
were isolated after passage through a series of graded sieves, The 
glomeruli  were then treated  with bacterial  collagenase  (Worthington 
Biochemical Corporation, Freehold, NJ) at 37~  for 30 min, and 
after extensive  washing, the glomerular remnants were plated onto 
tissue culture flasks  in RPMI 1640, supplemented with 20% FCS, 
2 mM t-glutamine, 2 mM sodium pyruvate, 5/zg/ml bovine in- 
sulin, 5 #g/ml human transferrin, 1% (vol/vol) nonessential  amino 
acids, and gentamicin. Cellular outgrowths appeared between days 
5 and 8, and all experiments were performed using cells between 
the fourth and tenth passage. The purity of the MC population 
was demonstrated as described in detail elsewhere (20). In brief, 
immunofluorescent staining demonstrated prominent intracellular 
staining for smooth muscle cell myosin, MHC class I antigen, 
vimentin, collagen IV, and flbronectin. The cells stained negative 
for Fc receptor, MHC II surface antigen, cytokeratin, and factor 
VIII, and were able to grow in D-valine-substituted medium. 
Preparation of Ligands.  AGE-BSA  and AGE-ribonuclease  were 
made by incubating BSA and bovine ribonuclease (Sigma Chem- 
ical Co., St. Louis, MO) with 0.5 M glucose-6-phosphate  (G-6-P), 
at 37~  for 4-6 wk in a 10 mM PBS buffer, pH 7.4, in the pres- 
ence of protease inhibitors and antibiotics as previously described 
(8). Unincorporated glucose was removed by dialysis against lx 
PBS. The concentration  of  AGE-BSA  was determined  by the method 
of Bradford (22), and the concentration of ribonuclease was deter- 
mined spectrophotometrically. AGE formed on either  BSA or 
ribonuclease was assessed based on characteristic absorption and 
fluorescence spectra (emission at 450 nm, excitation at 390 nm) 
(23) and quantitated by a radioreceptor assay using intact RAW 
264.7 cells grown in 96-well plates (11, 24). According  to this assay, 
AGE-BSA contained '~70 AGE U/rag (1 U of AGE is defined as 
the concentration of unknown agent required to produce 50% in- 
hibition of standard nSI-AGE-BSA  binding) and AGE-ribonuclease 
contained 62 AGE U/mg. 
To examine the effect of early glycosylation product reduction 
on ligand binding, AGE-BSA  was incubated with 200 molar excess 
NaBH4 (Sigma Chemical Co.) for 10 min at 4~  followed  by 1 h 
at room temperature. The reduced AGE-BSA was then dialyzed 
against lx  PBS, and the protein concentration was determined 
as above. The chemically  defined AGE, 2-furoyl-4-(5)-(2-furanyl)- 
1-H-imidazole (FFI), was synthesized and linked to BSA with 100 
mM water soluble carbodiimide as described previously (8). 
Iodination of  AGE-BSA.  AGE-BSA  was iodinated with carrier- 
free:2SI by the IODO-GEN method  (Bio-Rad Laboratories) of 
Fraker and Speck (25). Samples were dialyzed against PBS until 
>95% of radioactivity  was TCA precipitable and the samples were 
iodide free. 
Preparation  of  AGE Matrices.  Six-well  plates coated with rat tail 
collagen, type 1, human fibronectin, and polylysine  were purchased 
from Collaborative Research, Inc. (Bedford, MA). AGE matrices 
were produced by incubating the various matrix coated plates in 
0.5 M G-6-P, at 37~  for 2-3 wk in 10 mM PBS buffer (pH 7.4), 
as described for AGE-BSA. Control matrices were incubated under 
identical conditions in buffer alone. After incubation, the plates 
were washed extensively with lx  PBS. The amount of adhered 
collagen I was determined using a hydroxyproline  assay  (26), while 
adhered fibronectin and laminin were determined by the method 
of Lowry et al. (27) after dissolving the matrix in 2 N NaOH at 
Advanced Glycosylation  Endproduct Receptor on Mesangial Cells 37~  overnight, as described by Jones et al. (28), and by absor- 
bance at 280 nm. In both cases, similar  amounts of unmodified 
or AGE-modified matrix proteins  adhered (collagen I,  ,,~85%; 
fibronectin, "~70%; laminin, ,u80% of the plated amount remained 
attached to the plates). AGE levels in matrix proteins were quanti- 
tated by an AGE-specific radioreceptor assay, as described above (11, 
24) AGE-collagen I contained 47 AGE U/rag, AGE-fibronectin con- 
tained 54 AGE U/mg, and AGE-laminin contained 51 U/mg. Un- 
modified matrices contained <5 AGE U/rag protein. 
Membrane Preparation.  Rat  and human MC  were grown to 
confluency in 150-mm petri dishes. Cells were detached from the 
plates by PBS containing 3% EDTA and protease inhibitors (2 mM 
PMSF,  10/xg/ml aprotinin, 5 ng/ml pepstatin, and 1 mM 1,10- 
phenanthroline). After centrifugation, cells were disrupted with 
a tight Dounce homogenizer, pestle A, in a solution of PBS, with 
10 mM EDTA and protease inhibitors, as stated above. The nuclear 
and organelle-enriched fractions were removed by centrifugation 
at 13,000 g. Membranes were then isolated from the supernatant 
by centrifugation at 100,000 g for 1 h at 4~  The resulting en- 
riched membrane fraction was solubilized in PBS, containing 1% 
Triton X-100 and 2 mM PMSF. The protein concentration was de- 
termined by the method of Bradford (22). This material was then 
used for binding and ligand blotting studies. 
Binding Studies.  Filter binding studies were performed according 
to the method of Schneider et al. (29) and Daniel et al. (30) with 
minor modifications. 10-20 #g of  MC membrane protein was dot- 
blotted onto nitrocellulose filters.  The nitrocellulose filters were 
then cut and each dot was placed in a separate well of a 24-well 
plate. After blocking of the filters for I h at 4~  in PBS containing 
1.5% BSA, binding studies were initiated by adding various con- 
centrations of radioactive  ligand to the individual wells.  At 2 h, 
the nitrocellulose filters were washed three times with ice-cold lx 
PBS, and radioactivity bound was quantitated using a scintillation 
counter (Packard Tricarb, Paramus, NJ). Specific  binding was defined 
as the difference between total binding (radioligand incubated with 
membrane protein alone), and nonspecific binding (cells incubated 
with radiolabeled ligand plus  100-fold excess unlabeled ligand). 
Scatchard  analysis  of the data was  performed to determine the 
binding affinity constant and the receptor number, as described pre- 
viously (31).  Competition  studies  were performed in  a  similar 
manner to the binding studies, with the exception that the nitrocel- 
lulose filters were preincubated with the competitor for 1 h before 
adding the radiolabeled  ligand. 
Binding studies were also performed on confluent MCs in six- 
well plates.  The studies  were performed in 1 ml of RPMI  1640 
at 4~  after the addition of various concentrations of radioactive 
ligand, as described previously (8) and above. After 2 h of binding, 
the radioligand-containing  medium was removed, and the cells were 
washed with ice-cold PBS. The cell monolayer was then disrupted 
with 1% Triton X-100,  and the cell-associated radioactivity was 
quantitated. Protein concentration was determined by the method 
of Bradford (22). Specific binding was determined in an identical 
manner to that described above for the filter binding assay. 
Ligand Blotting.  MC membrane preparations (5-/~g aliquots) 
were subjected to electrophoresis on a nonreducing SDS-PAGE 
(10%), and then electroblotted onto a nitrocellulose filter, as previ- 
ously described (32). After blocking for 1 h in a solution of PBS 
containing 1.5% BSA,  the nitrocellulose filter was probed with 
lzSI-AGE-BSA in the presence of 100-fold excess of either BSA or 
AGE-BSA.  The blot was washed three times with lx  PBS and 
exposed to Kodak XAR-5 film at  -80~ 
Uptake and Degradation.  MC uptake and degradation was per- 
formed with a minor modification of previously described proce- 
dures (8). Briefly, MCs were grown to confluency in six-well plates 
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in DMEM containing 20% FCS and insulin. MC accumulation 
of radioactive ligand (AGE-BSA) was assessed by incubating cells 
with various concentrations of 12SI-AGE-BSA, in the presence and 
absence of 100-fold excess of unlabeled AGE-BSA, for 4 h at 37~ 
After washing the cells three times with ice-cold  PBS, the cells 
were solubilized in 1% Triton X-100 for 45 rain at room tempera- 
ture, and the amount of cell-associated radioactivity was determined. 
Specific uptake was defined by the same criteria as used for the MC 
binding  studies.  Protein concentration was  determined by the 
method of Bradford (22).  Degradation was determined by mea- 
suring TCA-soluble radioactivity in the aspirated  medium. 
Proliferation  Assays.  Rat MCs in DMEM containing 20% FCS 
were plated at 104 cells/well onto flat-bottomed 96-well microtiter 
plates, which had been pre-coated with different amounts of either 
AGE-modified or unmodified matrix proteins. 24 h later, the cells 
were washed with lx  PBS and incubated for an additional 48 h 
in medium containing 0.3% FCS. The cells were then labeled with 
2 #Ci of [3H]thymidine (Amersham Corp., Arlington Heights, 
IL) for 18-24 h, after which the supernatants were aspirated  and 
the cells in each well were harvested onto glass fiber filters with 
an automated cell harvester.  The amount of [3H]thymidine incor- 
porated was determined with a scintillation counter (Beckman In- 
struments).  To confirm thymidine incorporation data, parallel studies 
were carried out using an immunocytochemical assay system for 
detection of DNA  synthesis by measuring bromo-deoxyufidine 
(BrdU) incorporation (33), while in separate experiments, cells were 
trypsinized and counted in a particle counter (Coulter Electronics, 
Hialeah, FL). The data obtained by these two additional methods 
were consistent with  [3H]thymidine results (variations  between 
replicate wells  deviated  no more than 10%). 
Fibronectin Production.  Human  MCs  in  RPMI  1640  sup- 
plemented with 20% FCS were plated at 2  x  10  s cells per well 
onto six-well plates that had been coated with glucose-modified 
or unmodified matrix proteins. After 24 h, the cells were washed 
with lx  PBS and incubated in medium containing 0.3% FCS for 
48 h. The cells were then labeled in methionine-free medium for 
3 h with 200/xCi of 3SS-methionine and cysteine (Translabel; ICN, 
Plainview, NY). After labeling,  the medium was removed and the 
cell monolayers were washed with cold lx  PBS. The monolayers 
were extracted with 0.5 ml ofa 1-M urea solution containing 1 mM 
dithiothreitol (DTT), 10 mM Tris-HC1 (pH 7.4), 10 mM EDTA, 
and 2 mM PMSF, as previously described (34, 35). Fibronectin was 
then isolated from the medium and matrix by immunoprecipita- 
tion with an IgG purified anti-human fibronectin antibody (Cappel 
Laboratories,  Malvern, PA). Antifibronectin antibody was added 
to the samples and incubated overnight at 4~  To insure that any 
differences in fibronectin synthesis were not due to different number 
of cells/well, equal amounts of TCA-precipitable counts were im- 
munoprecipitated from each well. The immune complexes were 
isolated using protein A-Sepharose beads (Pharmacia Fine Chem- 
icals, Piscataway, NJ). After washing the protein A-Sepharose beads 
three times in 100 mM Tris HC1 (pH 7.4), 0.5% SDS, 0.5% Triton 
X-100, 2 mM PMSF, and 10 mM EDTA, fibronectin was released 
by heating at 100~  for 5 min in SDS-PAGE sample buffer,  and 
analyzed by gel electrophoresis and fluorography. The amount of 
fibronectin  from  each  sample  was  quantitated  by  slicing  the 
fibronectin band from the gel and determining 3SS-methionine and 
cysteine incorporation in a liquid scintillation counter. 
Results 
AGE-binding Site.  Membrane extracts isolated from both 
rat and human cultured MCs were found to contain binding 50  A  100  ~  ..~ 
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Figure  1.  Binding of 12SI-AGE-BSA to human (,'t) and rat (B) MC 
membranes. 10/~g of solubilized membrane protein from human and rat 
mesangial cells were dot-blotted onto nitrocellulose filters, which were 
then incubated with various concentrations of lzSI-AGE-BSA  in the pres- 
ence and absence of 100-fold  excess  unlabeled AGE-BSA. Specific  binding 
was obtained  by subtracting the nonspecific  binding from the total binding. 
The inset shows a Scatchard plot for the specific  binding (B =  pmol/ng 
membrane protein, F  =  nM). 
sites for AGE-modified proteins, using AGE-BSA as a model 
radioligand (Fig. 1). When MC membrane extracts were in- 
cubated  with  increasing  concentrations  of 12SI-AGE-BSA, 
specific binding increased in a saturable fashion. Half-maximal 
binding  was  observed  at  a  concentration  of AGE-BSA  of 
"~ 150 nM. Analysis of the specific binding data by Scatchard 
analysis indicated that both rat and human MCs  displayed 
similar binding characteristics.  Assuming  that each labeled 
AGE-BSA molecule can bind to only a single receptor site, 
the number of AGE molecules bound per cell ranged at 3.0 
_  0.25  x  105  molecules per cell with  a  binding  affinity 
constant of 2.0  _+  0.40  x  106 M- 1 (Kd  =  500 nM). Similar 
results were also obtained when binding  studies were per- 
formed on intact  cells at  4~  (data  not  shown). 
To confirm that  AGE modification of BSA was  respon- 
sible for binding  onto MC  surface,  competitive inhibition 
experiments were performed using either rat or human MC 
membrane  extracts  (Fig.  2).  These experiments  confirmed 
that  AGE  modification  of the protein was  responsible  for 
binding,  since excess cold AGE-BSA (Fig.  2, Ab  and Bb), 
(.4) and rat (B) MC membranes. 10 #g of solubilized membrane protein 
from human and rat MCs was dot-blotted onto nitrocellulose  filters. The 
filters were incubated with 50 nM *2SI-AGE-BSA  for 2 h at 4~  Com- 
petition experiments were performed in parallel experiments in which the 
radioligand was incubated with 100-molar excess of an unlabeled protein. 
Data shown are the average  of duplicate determinations, and are expressed 
as the percent maximal  binding. Maximal  binding was defined  as the amount 
of *2SI-AGE-BSA  bound in the presence of 100-molar excess cold BSA. 
Competitors used: (a) BSA, (b) AGE-BSA, (c) NaBH4-reduced  AGE-BSA, 
(d) FFI-BSA, (e) AGE-RNAse, ~  RNAse, (g) Collagen  I, (h) AGE collagen. 
but not unmodified BSA (Fig. 2, Aa and Ba), could competi- 
tively inhibit >80%  of 12SI-AGE-BSA binding to MC mem- 
brane extracts.  In addition,  other AGE proteins,  including 
AGE ribonuclease (Fig.  2, Ae and Be) and AGE collagen I 
(Fig. 2 Ah),  successfully inhibited 125I-AGE-BSA binding to 
MC membrane extracts. In sharp contrast, excess unmodified 
ribonuclease and collagen I failed to compete for binding (Fig. 
2, A f, B  f,  and Ag). 
To eliminate the possibility that early glycosylation prod- 
ucts were responsible for ligand binding, AGE-BSA prepara- 
tions were subjected to reduction using NaBH4. This agent 
effectively reduces the Shift base and Amadori  products to 
glucitollysine. The ability of reduced AGE-BSA to still com- 
pete effectively for *25I-AGE-BSA binding to MC membrane 
extracts suggests  that the ligand binding activity is due to 
moieties other than Amadori products, such as intermediate 
and advanced glycosylation adducts (Fig. 2, Ac and Bc). The 
ability of the chemically synthesized AGE (FFI)  to inhibit 
ligand binding was also assessed.  While FFI-BSA has been 
shown to bind to the macrophage AGE receptor, no compet- 
itive inhibition was exhibited by FFI-BSA for 125I-AGE-BSA 
binding to MC membrane extracts (Fig. 2, Ad and Bd). In 
this context, the MC receptor appears different from the mac- 
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(A) Uptake and degradation  of nSI-AGE-BSA  by rat MCs. 
MCs were incubated with various concentrations of nSI-AGE-BSA  for 4 h 
at 37~  The amount of cell-associated 12SI-AGE-BSA  (uptake),  and the 
amount of TCA-soluble counts in the medium (degradation)  were deter- 
mined in triplicate  wells.  (B) Accumulation  of 12SI-AGE-BSA  vs.  time. 
MCs in each well were incubated with 20 #g of 12SI-AGE-BSA  at 37~ 
and  specific cell-associated radioactivity  was determined  at various time 
intervals.  Cellular accumulation  of radioactivity  is expressed as the per- 
cent of the maximal accumulation  of 12SI-AGE-BSA. 
rophage FFI-binding AGE receptor, and similar to the en- 
dothelial AGE receptor, which does not recognize FFI-BSA 
(13). 
AGE Uptake and Degradation by MC at 37~  To deter- 
mine whether MCs can internalize and degrade AGE pro- 
teins,  cells were incubated with t2SI-AGE-BSA at 37~  and 
cell-assodated radioactivity was measured with respect to AGE- 
BSA concentration and length of incubation (Fig.  3, A  and 
B). When MCs were incubated at 37~  with increasing con- 
centrations of 12SI-AGE-BSA, specific cell-associated  radioac- 
tivity increased with increasing concentrations of radioactive 
ligand (Fig. 3 A). However, in contrast to the binding data, 
which exhibited saturable kinetics, MCs at 37~  continued 
to specifically  accumulate AGE-BSA even at concentrations 
as high as 1.1 #M.  Since the accumulation of AGE-BSA at 
37~  could represent both bound as well as internalized ligand, 
we compared accumulation of AGE-BSA at both 37~  and 
4~  Maximal  accumulation  of  12SI-AGE-BSA occurred 
within 2 h of incubation at 37~  (Fig. 3 B), while the amount 
of cell-associated radioactivity at 37~  was two- to fourfold 
higher  than  that  bound  at  4~  This,  coupled with  the 
different saturation kinetics, is consistent with the participa- 
Figure 4.  Ligand blot analysis 
of enriched  human  MC  mem- 
branes. 10/zg of solubilized mem- 
brane  protein  was  subjected  to 
electrophoresis on a nonreducing 
SDS/polyacrylamide  gel (10%). 
The  proteins  on  the  gel  were 
electroblotted  onto nitrocellulose 
membrane and probed with nsI- 
AGE-BSA in the presence of 100- 
fold excess of either BSA (lane a) 
or AGE-BSA (lane b). The anal- 
ysis presented is one of four iden- 
tical experiments. 
tion  of MCs  in  both  the binding  and  internalization  of 
AGE-BSA. 
Concomitant  with  the MC  accumulation of 12SI-AGE- 
BSA, ligand degradation also increased, as measured by a steady 
increase in TCA-soluble radioactivity in the media. The in- 
crease in AGE-BSA degradation paralleled the increase in MC 
uptake of AGE-BSA (Fig.  3 A). 
Ligand Blot.  To confirm and characterize better the AGE- 
binding sites on MCs, ligand blotting studies were performed 
using detergent extracts of MC membranes. As shown in 
Fig. 4, three prominent AGE-binding proteins of 50, 40, and 
30 kD were consistently observed. Binding of radiolabeled 
AGE to these membrane proteins was specific, since excess 
unlabeled AGE-BSA, but not BSA alone, could completely 
inhibit binding. The results were identical for both human 
and rat mesangial cells (human MC data shown). While it 
is possible that the lower molecular mass bands represent degra- 
dation products,  the isolation of membranes at 4~  in the 
presence of a variety of protease inhibitors,  as well as the 
reproducibility of results between experiments, argues against 
significant degradation. 
Inhibitory Effect of  AGE Matrices on [3H]Thymidine Incorpo- 
ration byMC.  The effects of unmodified and AGE-modified 
matrix proteins on MC proliferation were assessed (Fig.  5). 
MCs  grown  on  plates  containing  10  /~g/ml  unmodified 
fibronectin or collagen I exhibited greater [3H]thymidine in- 
corporation than cells plated on plastic.  AGE modification 
of these matrices, when used at a concentration of 10/~g/ml, 
resulted in a consistent decrease in [3H]thymidine uptake ap- 
proximating  the levels of incorporation of cells  plated on 
plastic.  While unmodified laminin substrates did not stimu- 
late the uptake of [3H]thymidine over control values,  AGE 
modification of laminin was associated with  a decrease in 
[3H]thymidine incorporation. This decrease was less marked 
than that observed after AGE modification of fibronectin and 
collagen IV. The observed differences in [3H]thymidine up- 
take were confirmed by BrdU incorporation assays, used to 
control for DNA synthesis (33),  and were not attributable 
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Figure 5.  Effects  of AGE-matrices on [3H]thymidine incorporation by 
MCs. Rat MCs were plated onto various matrices (10 #g/ml), as described: 
(a) fibronectin,  (b) AGE-fibronectin, (c) collagen I, (d) AGE-collagen-I, 
(e) laminin, ~  AGE-laminin. The results are expressed as the means  _+ 
SEM of six experiments and are expressed as the percent of [3H]thymi- 
dine incorporated relative to the control value, with control representing 
[3H]thymidine incorporated  by cells plated on plastic. 
to varying numbers of MCs adhering to the individual ma- 
trices; cell counting of adherent MCs 8 h  after plating re- 
vealed that a similar number of MC adhered to each matrix. 
AGE Matrices Stimulate Fibronectin Production.  To deter- 
mine whether MC interaction with AGE-modified matrices 
could enhance the production of fibronectin, MCs were plated 
onto either AGE-modified or unmodified collagen I, fibro- 
nectin,  and  polylysine.  Quantitative  analysis  of  adhered 
modified or nonmodified matrix components, e.g., collagen 
I and fibronectin,  indicated that identical amounts adhered 
onto the plastic surfaces. Fibronectin released into the medium 
or incorporated into the matrix was quantitated by immu- 
noprecipitation followed by PAGE, fluorography, and radio- 
activity determination as described in Materials and Methods. 
MCs grown on the AGE-modified matrices exhibited an in- 
crease in fibronectin secretion (Fig.  6). MCs grown on AGE 
collagen I, AGE fibronectin, and AGE polylysine released 33 
_+  3.6%,  54  _+  6.6%  and 48  _+  7.7%  more fibronectin, 
respectively, into the medium, compared to MCs grown on 
unmodified matrices (Fig.  6 A).  MCs grown on AGE ma- 
trices also incorporated more fibronectin into the matrix than 
cells  grown  on unmodified matrices  (Fig.  6 B). 
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Figure 6.  Effect of AGE matrices on fibronectin  synthesis by MCs. 
Human MCs were plated onto either unmodified or AGE-modified ma- 
trices and labeled with 3sS-methionine and cysteine, as described. The 
amount of fibronectin released into the medium (A),  and incorporated 
into the  matrices  (B), was  determined  by immunoprecipitation. The 
fibronectin bands on the gel were excised and counted for radioactivity. 
The values shown are expressed as the percent increase in fibronectin pro- 
duced by cells plated on the AGE matrices relative to that produced by 
cells plated on control unmodified matrices. The values show cpm/well 
and represent the means _+ SEM from four experiments. (a) Fibronectin, 
(b) polylysine, (c) collagen I. 
Discussion 
The results of this  study indicate that  both human  and 
rat MCs express binding sites that selectively recognize glucose- 
modified proteins. Evidence in favor of the existence of these 
sites includes several findings:  MC membranes are able to bind 
AGE-BSA, a model ligand, in a saturable fashion, exhibiting 
half-maximal  binding  at  a  concentration  of AGE-BSA  of 
"o150/~M. Binding of AGE-BSA to MCs is specific for the 
AGE adduct,  since several AGE-modified proteins, but not 
unmodified  proteins,  compete  for  binding.  In  addition, 
NaBH4-reduced AGE-BSA effectively competes for binding 
of AGE-BSA to MCs. This argues against (although not com- 
pletely excludes) the notion that the binding domain is related 
to an early product of nonenzymatic glycosylation, since the 
treatment of AGE-BSA with NaBH4 reduces both the Schiff 
base and Amadori products to glucitoUysine. Finally,  ligand 
blotting studies confirmed the presence of three membrane 
proteins with molecular masses of ,o50, "o40,  and "o30 kD 
that  specifically  bind AGE-BSA. 
In addition to binding AGE-BSA, MCs also appear to par- 
ticipate in both the uptake and degradation of AGE-BSA at 
37~  This is supported by several lines of evidence. First, 
MCs exposed to radiolabeled AGE-BSA at 37~  accumulate 
two- to fourfold more radioactivity than cells incubated at 
4~  for the same period of time.  Further evidence for the 
internalization of AGE-BSA is derived by comparison of the 
binding curves at 4~  and 37~  At 4~  MCs bind AGE- 
BSA in a saturable fashion.  However, at 37~  MCs con- 
tinue to accumulate 12SI-AGE-BSA in a nonsaturable manner 
up to concentrations of AGE-BSA as high as 1.1 #M. This 
increase in cell-associated radioactivity at 37~  could be at- 
tributed to slow internalization  of the AGE receptor com- 
plex with subsequent recycling of the receptors back to the 
cell surface after the intracellular release of AGE-BSA. A similar 
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receptor (36). Finally, MCs were found to degrade AGE-BSA 
slowly at 37~  with kinetics that paralleled those of AGE- 
BSA uptake. While the possibility remains that degradation 
of AGE-BSA occurs as a result of secreted proteases, the close 
association  between MC accumulation and degradation of 
AGE-BSA supports the participation of MC receptors in in- 
ternalizing and degrading AGE-BSA. 
This ability of MCs to slowly internalize and degrade AGE 
proteins points to a contributing role for MCs to the in vivo 
turnover and remodeling of senescent AGE-modified mesan- 
gial matrix proteins. However, the efficiency  with which MCs 
ingest and degrade AGE-BSA is only comparable to 10% of 
that which has been reported for the macrophage (8). In view 
of the fact that the kidney mesangium contains blood-derived 
macrophages as well as kidney MCs (37), the relative contri- 
bution of each cell type to the in vivo turnover of senescent 
mesangial proteins may differ considerably,  and remains to 
be defined. 
The relationship between this AGE receptor identified on 
the MC and the AGE receptor reported on monocytes/mac- 
rophages and ECs has not been completely clarified. Within 
a given cell lineage,  the AGE receptor is highly conserved 
between mouse, rat, and human cells. Functionally, both the 
rat and the human MC AGE receptors exhibit similar binding 
characteristics, and structurally both yield AGE-binding pro- 
teins of similar molecular mass as estimated by ligand blot 
studies. Likewise, the murine and human macrophage AGE 
receptors display similar structural and functional character- 
istics (38, 39). However, while the AGE receptors on all three 
cell  types are  similar in that  they all recognize advanced 
glycosylation products, several differences exist (8, 13). The 
Kas for the receptors are different; the Kas for the macro- 
phage and EC AGE receptor are m70-100 riM,  while the 
Ka for the MC is about fivefold higher.  In addition, the 
efficiencies with which these receptors internalize and degrade 
AGE proteins are different. Macrophages ingest and degrade 
AGE-BSA at a much higher rate than either ECs or MCs. 
Finally, the macrophage AGE receptor recognizes the specific 
adduct FFI, which is not recognized by either the MC receptor 
or the EC receptor. These differences between AGE receptors 
of different cell types suggest that distinct subclasses of the 
receptor exist. In the case of MCs, preliminary structural evi- 
dence suggests that these receptors consist of a diverse group 
of peptides of different molecular masses and possibly function. 
To determine whether the interaction of MCs with AGE- 
modified matrix proteins could influence MC function, MCs 
were plated onto AGE matrices.  Since MC hyperplasia  has 
been reported in the diabetic kidney, we were first interested 
in assessing whether plating MCs on AGE matrices could 
stimulate MCs to proliferate.  In contrast to the increase in 
MC number which has been reported in the diabetic kidney 
(3),  MCs plated on AGE matrices exhibited a decrease in 
proliferation as measured by [3H]thymidine incorporation. 
Crowley et al. (40) also found that MC proliferation was in- 
hibited when MCs were grown on MC-generated matrices 
that had been nonenzymatically glycosylated with glycoalde- 
hyde. One possibility that could account for the discrepancy 
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between this in vitro result and in vivo findings is that MC 
proliferation in vivo is not mediated by a direct interaction 
of AGE matrix proteins with MCs. In vivo, the interaction 
of MCs with other components of the glomerular mesan- 
gium, such as blood-derived macrophages, could provide a 
paracrine proliferative stimulus to MCs in the diabetic kidney. 
The interaction of macrophages with AGEs has been shown 
to  induce  the  release  of a  variety  of cytokines,  such  as 
cachectin/TNF and II:1, which could have paracrine growth- 
promoting effects on MC in vivo (14). 
Increased mesangial accumulation of fibronectin has been 
noted in humans and experimental animals with diabetic 
kidney disease (4, 5).  In addition, the presence of elevated 
fibronectin mRNA levels in kidneys from diabetic animals 
(41) indicates that enhanced synthesis of fibronectin accounts 
for at least part of the increased accumulation. The observa- 
tion that the interaction of MCs with AGE matrices in vitro 
induces an increase in fibronectin secretion suggests that in 
vivo, the interaction of MCs with AGE-modified matrices 
may stimulate MCs to enhance synthesis of this important 
matrix component. 
Recent experimental findings have documented the impor- 
tance of ambient glucose concentration in modulating cell 
function (42-44). Incubation of MCs in high glucose medium 
leads to a diminished rate of proliferation, along with in- 
creased  production of several matrix  proteins,  including 
fibronectin, collagen IV, and laminin. The findings reported 
here provide an additional mechanism by which elevated glu- 
cose levels, acting through AGE modification of matrix pro- 
teins, may alter MC function. In addition, it is possible that 
some of the functional alterations detected in the elevated 
glucose  medium  may  actually  have  resulted  from  AGE 
modification of existing matrix proteins, since a time delay 
of several days in high glucose medium was necessary before 
alterations  in MC function became apparent. 
The upregulation of fibronectin mRNA in kidneys from 
diabetic animals has been found to persist for several weeks 
after the restoration of normoglycemia (41). Since the for- 
mation of AGEs occurs in an irreversible fashion, it follows 
that the "memory" of a prior elevated glucose concentration 
should persist in the form of AGE moieties within long-lived 
matrix proteins. The continued interaction of these altered 
proteins with MCs, despite restoration of normoglycemia, 
may be one of the stimuli for MCs to continue producing 
fibronectin. This finding may also help to explain the difficulty 
encountered in treating clinical diabetic kidney disease. Once 
kidney disease has occurred, controlling of ambient glucose 
concentration does little to avert the progression of disease 
(45).  While many mechanisms undoubtedly contribute to 
this phenomenon, the continued interaction between AGE- 
modified matrices and kidney MCs may contribute to the 
progressive functional abnormalities, despite normalization 
of blood glucose levels. 
At present it is not clear whether the alteration in MC 
function associated with exposure to AGE matrices is medi- 
ated via the MC AGE-binding sites. In this regard, we have 
been unable to demonstrate these functional alterations using 
a soluble AGE ligand. However, it is known that the ability of a ligand to crosslink its receptor may be critical for signal 
transduction (46), While soluble ligands may not be able to 
perform this function, ligands adhering to a cell surface ac- 
quire the ability to crosslink their receptor. This phenomenon 
could provide one mechanism whereby AGE matrices could 
interact with AGE receptors, while soluble AGE ligands can 
not. 
Alternatively,  it is possible that  the formation  of AGEs 
on matrix proteins may affect MC function by altering normal 
matrix-matrix and matrix-cell interactions distinct from the 
AGE receptor pathway. The formation of AGEs on matrix 
proteins results in protein crosslinking that could cause the 
distortion  of important  protein  recognition  sites  through 
mechanisms  unrelated  to the AGE receptors.  The binding 
of anionic proteoglycans, such as heparin sulfate, to matrix 
proteins is reduced after AGE modification (47).  Similarly, 
the ability of fibronectin to bind collagen is impaired after 
AGE modification (48). These effects of glycosylation may 
alter the composition of matrix. Matrix proteins are also able 
to interact with distinct receptors on MCs, and this interac- 
tion is important in the regulation of cell adhesion, cell growth, 
and gene expression (49).  Glycosylation of matrix proteins 
may alter their recognition by cellular receptors. It is there- 
fore conceivable that nonenzymatic glycosylation of normal 
matrix proteins,  by altering normal matrix composition and/or 
distorting  normal cellular recognition sites for matrix pro- 
teins, may produce some of the functional changes observed 
in MC phenotype. 
The studies reported here represent the identifcation and 
initial characterization of mesangial cell surface binding pro- 
teins that recognize AGE proteins, and provide a mechanistic 
basis whereby AGE-modification of matrix proteins in the 
kidney may lead to alterations of MC function. We demon- 
strated that MCs plated on AGE-modified matrices exhibit 
altered functional characteristics,  including enhanced produc- 
tion of fibronectin and decreased proliferation.  Many ques- 
tions remain to be addressed; in particular,  the relationship 
between AGE receptors reported on different cell types, and 
the relationship  of the MC AGE-binding proteins to other 
known MC receptors remain to be elucidated. We can now 
begin to explore the range of biological effects that may be 
modulated via these molecules, and to investigate the in vivo 
role  that  they  may  play  in  maintaining  normal  kidney 
homeostasis.  Finally,  we can begin to assess the degree to 
which these receptors may contribute to the development of 
diabetic renal complications. 
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